New Antibiotic Effective in Treating Gram-Positive Bacteremia

OncologyONCOLOGY Vol 14 No 3
Volume 14
Issue 3

Results from the compassionate use program for linezolid (Zyvox), an investigational new antibiotic still under development, show that the drug is effective in the treatment of patients with bacteremia associated with significant gram-positive infections,

Results from the compassionate use program for linezolid (Zyvox), an investigational new antibiotic still under development, show that the drug is effective in the treatment of patients with bacteremia associated with significant gram-positive infections, including those resistant to current therapies. These data were discussed at a poster session at the 37th annual meeting of the Infectious Diseases Society of America in Philadelphia.

Data were presented on 254 patients with bacteremia from 165 investigational sites. Of the total bacteremic population enrolled in the compassionate use program, 120 were clinically evaluable at short-term follow-up. Of this group, 82.5% were considered to be cured. A total of 64 patients were considered to be microbiologically evaluable at short-term follow-up, and linezolid demonstrated an 85.9% microbiologic cure rate in these individuals.

A third group of 50 patients was studied to assess how rapidly linezolid eradicated the bacteria from patients’ bloodstream. Linezolid eradicated organisms from the bloodstream by day 2 of treatment in approximately 50% of these patients and by day 5 in 75%.

 “Our data from the Zyvox compassionate use program suggest that Zyvox is well tolerated and successful in treating patients with bacteremia,” said study coordinator Mary Birmingham PharmD, program director, The Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, and State University of New York, Buffalo. “Zyvox is an excellent treatment option for these seriously ill patients with gram-positive bacteremia.”

Range of Infections Treated

The infections in the patients studied included documented intravenous or catheter-line infections, gastrointestinal infections, skin and soft-tissue infections, urinary tract infections, infected thrombi, and infected devices. The primary causative organism isolated from from the group was vancomycin-resistant Enterococcus faecium (81.4%). Other organisms isolated included methicillin-resistant Staphylococcus aureus (6.2%), methicillin-resistant S epidermidis (2.7%), other strains of vanco-mycin-resistant entercocci (2.7%), vancomycin-susceptible enterococci (2.7%), vancomycin-resistant E faecalis (2.3%), and methicillin-susceptible S aureus (1.2%).

Nonevaluability in a large number of patients was due to repeat baseline blood cultures being negative prior to the initiation of treatment with linezolid or to patients dying from their underlying illnesses. The overall adverse event rate was 25.2%, with 5.5% of these events considered to be serious and 9.0% requiring discontinuation of treatment.

Articles in this issue

Comparative Economic Analysis of the Treatment of Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL) in France Using CHOP, Fludarabine, or Rituximab
FHIT Gene, Smoking, and Cervical Cancer
Final Report on the Safety and Efficacy of Retreatment With Rituximab for Patients With Non-Hodgkins Lymphoma
Prospective, Randomized, Controlled Study of Zevalin Radioimmunotherapy Compared to Rituximab Immunotherapy for B-Cell, Non-Hodgkins Lymphoma: Interim Results
IOM Medical Error Estimates Questioned, But Legislation Considered
Less Toxic Therapies for Hodgkin’s Disease May Reduce Secondary Cancers
Preserving Fertility in Young Women With Ovarian Cancer Does Not Decrease Survival
Iodine-131 Tositumomab for Patients With Transformed, Low-Grade Non-Hodgkin’s Lymphoma: Overall Clinical Trial Experience
Survival Rates Significantly Worse For African-Americans With Endometrial Cancer
Rituximab Has Significant Activity in Patients With Chronic Lymphocytic Leukemia
Responders to Rituximab Show Continued Tumor Regression Over Time and a Progression-Free Survival That Correlates With Response Classification
PhRMA Criticizes FDA’s Proposed Rule on Antibiotic Approvals
Phase II Study of Rituximab in Combination With CHOP in Patients With Previously Untreated Intermediate- or High-Grade Non-Hodgkin’s Lymphoma
New Antibiotic Effective in Treating Gram-Positive Bacteremia
Reduced-Dose Zevalin Radioimmunotherapy for Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma Patients With Preexisting Thrombocytopenia: Report of Interim Results of a Phase II Trial
Related Videos
Experts on multiple myeloma
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Experts on multiple myeloma
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
Experts on MM
Experts on colorectal cancer
Experts on MM
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Experts on multiple myeloma